Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits CMA for its Covid-19 vaccine booster  

Moderna has submitted a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level.  “We are pleased to submit for a conditional marketing approval with the EMA for our booster candidate at the 50… Read More

#Covid-19 #News #Trending News

#Biopharmaceuticals #Drug development #Webinar

Webinar: learn how to accelerate biosimilar development

Using an automated CE-SDS platform in efficient biosimilar comparability studies is a free-to-attend webinar which will be hosted by DDW and supported by Bio-Techne on 29 September at 4PM BST. Watch on Demand here. Join Dr Richard L Easton, Technical Director of Structural Analysis at BioPharmSpec as he discusses… Read More

#News #Trending News

#Autoimmune disease #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

NIH studies Covid-19 vaccine dose for people with autoimmune disease 

The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.   The trial will also investigate whether pausing… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Pfizer

This week in drug discovery (23-27 August) 

News round-up by DDW’s Megan Thomas for 23-27 August  The Covid-19 pandemic has undoubtedly put virology back on the drug discovery map and this week, DDW’s Megan Thomas has rounded up five stories which show updates and advancements in the fight against the virus.  … Read More

#News #Trending News

#Cancer research #Clinical trials #Drug development #Drug discovery #Institute of Cancer Research

New cancer drug to enter first clinical trial targeting HSF1 pathway 

The Institute of Cancer Research (ICR), London has discovered an investigational drug called NXP800, which cancer patients are set to receive for the first time. It was discovered in a Phase I clinical trial sponsored by an oncology-focused biopharmaceutical company, Nuvectis Pharma.  The investigational oral drug inhibits the so-called… Read More

#Cancer Research #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna

Japan suspends 1.6 million Moderna doses over contamination fears 

Japan has suspended the use of around 1.63 million doses of the Moderna vaccine due to contamination, which the health ministry confirmed resulted from “foreign materials” in an unused batch of roughly 560,000 vials, according to BBC reports.   According to the news site, Takeda Pharmaceutical, which sells and distributes… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits BLA to FDA for Covid-19 vaccine 

Moderna has completed the rolling submission process for its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the full licensure of the its Covid-19 vaccine for active immunisation to prevent Covid-19 in individuals 18 years of age and older. As part of the completed BLA submission, Moderna has requested Priority… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer #Regulatory

Full FDA approval for Pfizer-BioNTech Covid-19 vaccine 

The US Food and Drug Administration (FDA) has approved the Biologics License Application for the Pfizer-BioNTech Covid-19 vaccine. It will now be marketed as Comirnaty for the prevention of Covid-19 disease in individuals 16 years of age and older.  It is the first COVID-19 vaccine to be granted approval by the FDA.  The vaccine continues to… Read More

#Covid-19 #News #Trending News

#Assays #Biosciences #Protein chemistry / Proteomics

Protein-protein Interactions Using NanoBRET Technology

In this video, Dr Gary Allenby, CEO Aurelia Bioscience, describes a scientific poster on ‘Protein-protein Interactions Using NanoBRET Technology’. Historically, only solution-based assays were used to screen compounds in PPI, but a more physiological approach is to examine the interaction in living cells. However, there are very few… Read More

#News #Trending News #Videos

#Cancer #Cancer research #Clinical trials #Drug repurposing

Aspirin trialled as potential treatment for aggressive breast cancer 

A new study is trialling whether giving aspirin alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.   The clinical trial is being funded by the Breast Cancer Now Catalyst Programme, which aims to accelerate progress in breast cancer research through innovation and collaboration. As… Read More

#Cancer Research #News #Trending News

#Covid-19 #Healthcare #Monoclonal antibodies

First monoclonal antibody treatment for Covid-19 approved for UK 

Following a thorough review of evidence carried out by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommendation by the Commission on Human Medicines (CHM), the UK government’s independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the… Read More

#Covid-19 #News #Trending News

#Biotherapeutics #Collaboration #Funding #HIV #Pharma

This week in drug discovery (16-20 August) 

News round-up by DDW’s Megan Thomas for 16-20 August  DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research.   1. OGT training initiative with CytoCell University … Read More

#News #Trending News

#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies

Monoclonal antibody prevents malaria in NIH trial 

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More

#News #Trending News

#Automation / robotics #Drug discovery #ELRIG #Events #Screening #SLAS

ELRIG’s Drug Discovery 2021 to host SLAS’s Innovation AveNEW 

The European Laboratory Research & Innovation Group (ELRIG) UK has announced programme details for Drug Discovery 2021, which will take place at the Exhibition Centre ACC in Liverpool, UK, from October 19–20. The Society for Laboratory Automation and Screening (SLAS) will host its Innovation AveNEW to showcase emerging innovations and companies. … Read More

#News #Trending News

#Automation / robotics #Events #Screening #SLAS 2021

Applications open to SLAS’ Innovation AveNEW exhibition programme 

The Society for Laboratory Automation and Screening (SLAS) is expanding its Innovation AveNEW exhibition programme to include venues and events in Spain, Berlin, London and Boston in order to provide more opportunities for laboratory technology and automation startups to get the recognition and attention they need to succeed. Applications are now open. … Read More

#News #Trending News

#Alzheimer's #Drug development #Funding #Research

NIH awards $15 million for Alzheimer’s research

The National Institute of Aging (NIA), part of the National Institutes of Health, has awarded Wake Forest School of Medicine $15.2 million over five years in support of its research centre for Alzheimer’s disease. Established in 2016 with a multimillion-dollar NIA grant, the Alzheimer’s Disease Research Center (ADRC) at Wake… Read More

#News #Trending News